Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice
Aim. To evaluate the effect of PCSK9-targeted therapy on lipoprotein(a) (Lp(a)) levels in patients with atherosclerotic cardiovascular diseases who have not achieved the target low-density lipoprotein cholesterol (LDL-C) level (statins at maximum tolerated doses and/or ezetimibe).Material and method...
| Príomhchruthaitheoirí: | , , , , , |
|---|---|
| Formáid: | Alt |
| Teanga: | Russian |
| Foilsithe / Cruthaithe: |
«FIRMA «SILICEA» LLC
2025-01-01
|
| Sraith: | Российский кардиологический журнал |
| Ábhair: | |
| Rochtain ar líne: | https://russjcardiol.elpub.ru/jour/article/view/6177 |